Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arrowhead Research has increased its ownership of majority owned subsidiary Calando Pharmaceuticals through the exchange of Calando Series A Preferred Stock for Arrowhead warrants.
Subscribe to our email newsletter
The exchange follows recent milestones achieved by Calando, including several notable first accomplishments in RNAi technology that include proof of the first definitive systemic siRNA delivery and first to show RNAi mediated knockdown of target mRNA and protein in humans.
Arrowhead CEO Christopher Anzalone said that the acquisition of majority block of Calando Series A stock is a good transaction as it increases their ownership in Calando and enables additional flexibility as they work to negotiate the right partnership or series of partnerships for Calando’s industry leading RNAi delivery platform and exciting therapeutic candidate, CALAA-01.
“Calando is making continued progress toward completing the phase 1 clinical trial of CALAA-01 and interfacing with potential strategic partners,” Anzalone said.
Arrowhead Research is a nanotechnology company commercialising new technologies in the areas of life sciences, electronics, and energy.